1-3 of 3
Liliana Franca Devizzi, MD
Close
Sort by
Journal Articles

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

Anna Dodero, MD, Anna Guidetti, MD, Fabrizio Marino, MD, Cristiana Carniti, PhD, Stefania Banfi, Alessandra Tucci, MD, Monica Balzarotti, Antonello Domenico Cabras, MD, Valentina Monti, PhD, Liliana Franca Devizzi, MD, Lucia Farina, MD, Maria Chiara Di Chio, MD, Giuseppe Rossi, Carmelo Carlo-Stella, MD, Paolo Corradini
Journal: Blood
Blood (2019) 134 (Supplement_1): 4116.
https://doi.org/10.1182/blood-2019-124350
Published: 2019
Journal Articles

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

Anna Dodero, MD, Anna Guidetti, MD, Alessandra Tucci, MD, Alessio Pellegrinelli, Antonello Cabras, MD, Liliana Franca Devizzi, MD, Lucia Farina, Luca Pappalettera, MD, Alberto Mussetti, MD, Maria Chiara Di Chio, MD, Rosa Jessica, MD, Martina Soldarini, MD, Angela Passi, MD, Paola Matteucci, MD, Stefano A. Pileri, Giuseppe Rossi, MD, Paolo Corradini, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2844.
https://doi.org/10.1182/blood.V130.Suppl_1.2844.2844
Published: 2017
Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD
Journal: Blood
Blood (2016) 128 (22): 3009.
https://doi.org/10.1182/blood.V128.22.3009.3009
Published: 2016